# CCR8 orchestrates an immunosuppressive niche in the liver to promote Echinococcus multilocularis infection

**Authors:** Jiao Hou, Haining Fan

PMC · DOI: 10.1371/journal.pntd.0014018 · 2026-03-06

## TL;DR

The study shows that the CCR8/CCL1 pathway helps the Echinococcus multilocularis parasite suppress the immune system in the liver, and blocking it could lead to better treatments.

## Contribution

The study identifies CCR8 as a novel immunotherapeutic target for alveolar echinococcosis by revealing its role in creating an immunosuppressive environment.

## Key findings

- The CCR8/CCL1 axis recruits Tregs and functionally impaired T cells to the liver during E. multilocularis infection.
- CCR8 deficiency in mice reduces liver lesions and improves immune response by enhancing CD4+ and CD8+ T cell activity.
- Blocking CCR8 reverses the immunosuppressive niche, promoting a Th1 immune response against the parasite.

## Abstract

Echinococcus multilocularis (E. m) infection causes alveolar echinococcosis (AE), a serious zoonotic disease characterized by invasive larval growth in the liver. The parasite establishes a chronic infection, suggesting effective modulation of host immunity. Here, we investigated the role of the CCR8/CCL1 chemokine axis in shaping the hepatic immune microenvironment during E.m infection. In infected wild-type (WT) mice, chronic infection specifically activated the hepatic CCR8/CCL1 axis, which was associated with a marked accumulation of FOXP3+ regulatory T cells (Tregs). Notably, although CCR8+ T cells expanded numerically, their production of effector (IFN-γ, TNF-α, and perforin) was significantly impaired. In contrast, infected CCR8-knockout (KO) mice developed smaller hepatic lesions, exhibited a reduction in liver weight, and had significantly lower serum ALT levels. Mechanistically, CCR8 deficiency enhanced the effector functions of CD4+ and CD8+ T cells, skewing the immune response towards a Th1 phenotype, and partially reversed the immunosuppressive milieu. Our findings establish that the CCR8/CCL1 axis drives the formation of an immunosuppressive niche in the liver by recruiting both Tregs and functionally suppressed CCR8+ T cells, thereby facilitating parasite immune evasion. This study not only elucidates a pivotal mechanism of immune escape in AE but also identifies CCR8 as a promising novel immunotherapeutic target for this neglected tropical disease.

The parasite Echinococcus multilocularis causes a devastating liver disease, forming tumor-like growths that are difficult to treat. A major reason for its success is its ability to “switch off” the body’s immune defenses in the liver. We investigated a specific communication signal in cells, known as the CCR8/CCL1 pathway, to understand how the parasite achieves this. We discovered that the parasite activates this pathway, which acts like a homing beacon for the liver. This beacon attracts two types of problematic cells: powerful immune-suppressing cells (Tregs) and, surprisingly, normal immune fighter cells (T cells) that become functionally impaired. While these fighter cells are present in large numbers, they lose their ability to attack the parasite. When we genetically removed the CCR8 signal in mice, the immune system fought back effectively. These mice had much healthier livers and smaller parasite lesions because their immune cells remained active and potent. Our work shows that blocking the CCR8 pathway can reverse the parasite’s immune-suppressing tricks, revealing a promising new strategy for treating this serious disease.

## Linked entities

- **Genes:** CCR8 (C-C motif chemokine receptor 8) [NCBI Gene 1237], CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 6346], FOXP3 (forkhead box P3) [NCBI Gene 50943]
- **Diseases:** alveolar echinococcosis (MONDO:0017282), Echinococcus multilocularis infection (MONDO:0017282)
- **Species:** Echinococcus multilocularis (taxon 6211), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Ccl1 (C-C motif chemokine ligand 1) [NCBI Gene 20290] {aka I-309, P500, Scya1, Tca-3, Tca3}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, TNF (tumor necrosis factor) [NCBI Gene 397086] {aka TNFSF2, TNFa}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}, LAG3 (lymphocyte activating 3) [NCBI Gene 100125962] {aka CD223, LAG-3}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Cd247 (CD247 antigen) [NCBI Gene 12503] {aka 4930549J05Rik, A430104F18Rik, Cd3, Cd3-eta, Cd3-zeta, Cd3h}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, CD4 (CD4 molecule) [NCBI Gene 404704], Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Il2ra (interleukin 2 receptor, alpha chain) [NCBI Gene 16184] {aka CD25, Il2r, Ly-43}, CCR8 (C-C motif chemokine receptor 8) [NCBI Gene 1237] {aka CC-CKR-8, CCR-8, CDw198, CKRL1, CMKBR8, CMKBRL2}, CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 100310829], IFNG (interferon gamma) [NCBI Gene 396991], CCR8 (C-C motif chemokine receptor 8) [NCBI Gene 100622393], Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 6346] {aka I-309, P500, SCYA1, SISe, TCA3}, Ccr8 (C-C motif chemokine receptor 8) [NCBI Gene 12776] {aka C-C, C-C CKR-8, CC-CKR-8, CCR-8, CKR-8, Cmkbr8}
- **Diseases:** hepatocellular carcinoma (MESH:D006528), parasite (MESH:D010272), liver infection (MESH:D017093), pathological damage (MESH:D005598), hepatic lesions (MESH:D056486), AE (MESH:C536591), cytotoxic (MESH:D064420), E.m infection (MESH:D004927), immune cell dysfunction (MESH:D007154), infected (MESH:D007239), viral infections (MESH:D014777), hepatomegaly (MESH:D006529), hepatocyte damage (MESH:D020263), Schistosoma mansoni infection (MESH:D012555), neglected tropical disease (MESH:D058069), autoimmune disease (MESH:D001327), liver fibrosis (MESH:D008103), cancer (MESH:D009369), leishmaniasis (MESH:D007896), fibrosis (MESH:D005355), inflammation (MESH:D007249), cystic echinococcosis (MESH:D004443), liver disease (MESH:D008107), chronic hepatic infection (MESH:D006521)
- **Chemicals:** DAPI (MESH:C007293), DAB (MESH:C000469), paraformaldehyde (MESH:C003043), SYBR Green (MESH:C098022), albendazole (MESH:D015766), ionomycin (MESH:D015759), Monensin (MESH:D008985), 15596026CN (-), TRIzol (MESH:C411644), paraffin (MESH:D010232), Brefeldin A (MESH:D020126)
- **Species:** Homo sapiens (human, species) [taxon 9606], Echinococcus multilocularis (species) [taxon 6211], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** P1701H
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965546/full.md

---
Source: https://tomesphere.com/paper/PMC12965546